Business Description
Intellia Therapeutics Inc
NAICS : 325413
SIC : 2835
ISIN : US45826J1051
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 6.5 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -0.21 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 3.56 | |||||
Beneish M-Score | -1.24 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -26.6 | |||||
3-Year EBITDA Growth Rate | -34.8 | |||||
3-Year EPS without NRI Growth Rate | -31.2 | |||||
3-Year FCF Growth Rate | -68.8 | |||||
3-Year Book Growth Rate | 12.4 | |||||
Future 3-5Y EPS without NRI Growth Rate | -2.01 | |||||
Future 3-5Y Total Revenue Growth Rate | 48.72 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 47.89 | |||||
9-Day RSI | 47 | |||||
14-Day RSI | 46.41 | |||||
6-1 Month Momentum % | -12.12 | |||||
12-1 Month Momentum % | -30.78 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.21 | |||||
Quick Ratio | 7.21 | |||||
Cash Ratio | 6.58 | |||||
Days Sales Outstanding | 153.66 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12 | |||||
Shareholder Yield % | -8.69 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -1140.05 | |||||
Net Margin % | -1106.87 | |||||
FCF Margin % | -831.93 | |||||
ROE % | -48.93 | |||||
ROA % | -40.26 | |||||
ROIC % | -123.21 | |||||
ROC (Joel Greenblatt) % | -349.72 | |||||
ROCE % | -45.11 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 48.24 | |||||
PB Ratio | 2.39 | |||||
Price-to-Tangible-Book | 2.39 | |||||
EV-to-EBIT | -3.34 | |||||
EV-to-Forward-EBIT | -2.94 | |||||
EV-to-EBITDA | -3.4 | |||||
EV-to-Forward-EBITDA | -2.99 | |||||
EV-to-Revenue | 38.05 | |||||
EV-to-Forward-Revenue | 33.29 | |||||
EV-to-FCF | -4.73 | |||||
Price-to-Net-Current-Asset-Value | 4.32 | |||||
Price-to-Net-Cash | 4.93 | |||||
Earnings Yield (Greenblatt) % | -29.93 | |||||
FCF Yield % | -16.39 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Intellia Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 42.562 | ||
EPS (TTM) (€) | -5.074 | ||
Beta | 1.12 | ||
Volatility % | 70.54 | ||
14-Day RSI | 46.41 | ||
14-Day ATR (€) | 0.804677 | ||
20-Day SMA (€) | 20.81375 | ||
12-1 Month Momentum % | -30.78 | ||
52-Week Range (€) | 18.46 - 36 | ||
Shares Outstanding (Mil) | 101.58 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Intellia Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Intellia Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Intellia Therapeutics Inc Frequently Asked Questions
What is Intellia Therapeutics Inc(FRA:38I)'s stock price today?
When is next earnings date of Intellia Therapeutics Inc(FRA:38I)?
Does Intellia Therapeutics Inc(FRA:38I) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |